Combined glaucoma screening during diabetic eye exams
Official title: The Glaucoma and Retinopathy Screening Study (GRaSS)
Run by Massachusetts Eye and Ear Infirmary · NCT06882356 · Data updated 2026-11-12
This program tests whether adding an AI review of retinal photos, a quick eye pressure check, and a virtual-reality side-vision test to routine diabetic eye screening helps find glaucoma earlier in people with diabetes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Massachusetts Eye and Ear Infirmary Academic / other |
| Locations | 7 sites (Boston, Massachusetts and 6 other locations) |
| Status | Recruiting |
| Started | July 16, 2025 |
| Main results expected | September 2030 |
| Study ends | September 2030 |
| Registry record updated | August 27, 2026 |
| Trial ID | NCT06882356 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with diabetes who are undergoing diabetic retinopathy screening using the LumineticsCore system at one of the participating primary care centers and who can give informed consent are ideal candidates.
✕Probably not a fit
People without diabetes, those not screened with the LumineticsCore workflow at participating sites, or patients with already-known or very advanced glaucoma are unlikely to gain additional benefit from the added screening components.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective interventional program that embeds an AI-based glaucoma screen into existing diabetic eye disease screenings at community primary care centers. Participants receive fundus photography analyzed by an AI algorithm (LumineticsCore), measurement of intraocular pressure, and a virtual-reality visual field test when indicated. The approach targets people with diabetes because they have higher risk for glaucoma and already attend retinal photo screening. The goal is to increase detection of undiagnosed glaucoma and enable earlier treatment while using existing screening encounters.
Why it matters
Potential benefit: If successful, the program could identify glaucoma earlier in high-risk patients with diabetes so treatment can begin sooner and vision loss may be reduced or delayed.
How similar studies have gone: AI systems have shown good performance for diabetic retinopathy detection and some optic nerve changes on fundus photos, but AI-based glaucoma screening combined with virtual-reality visual field testing is less extensively validated and remains an active area of research.
Who can join: the full rules
Show full inclusion / exclusion criteria
* Individuals with diabetes undergoing AI-based screening for diabetic retinopathy using the LumineticsCore (Digital Diagnostics) system at primary care centers. * Individuals who are able and willing to provide informed consent for participation in the study.
Where it's running
-
Massachusetts General Hospital Internal Medicine Associates
Boston, Massachusetts, United States Recruiting -
Brigham and Women's Primary Care Associates of Longwood
Boston, Massachusetts, United States Recruiting -
Massachusetts General Hospital Broadway Primary Care-Revere
Boston, Massachusetts, United States Recruiting -
MGH Chelsea HealthCare Center
Chelsea, Massachusetts, United States Recruiting -
NSPG Lynn
Lynn, Massachusetts, United States Recruiting -
NSPG Saugus
Saugus, Massachusetts, United States Recruiting
Show 1 more location
-
NSPG Salem
Salem, Massachusetts, United States Not yet recruiting
Study contacts
- Principal investigator: David S Friedman, MD, PhD, MPH — Massachusetts Eye and Ear
- Study coordinator: David S Friedman, MD, PhD, MPH
- Email: grass@mgb.org
- Phone: 617-573-3094
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Balance training for people with glaucoma
A randomized study tests whether a structured eight-week balance program helps adults with glaucoma improve balance, reduce fall risk, and lessen fear of falling.
-
Eye drops Rhopressa vs Timolol to protect nerve cells in glaucoma
In adults with open-angle glaucoma, this study tests whether Rhopressa helps preserve retinal nerve cells better than Timolol while both lower eye pressure.
-
Comparison of FT-1000 non-contact tonometry with Goldmann applanation tonometry in glaucoma patients
This study tests whether the FT-1000 non-contact tonometer gives measurements that agree with the Goldmann applanation tonometer in adults with glaucoma.
-
Removing the ripcord from a glaucoma drainage device after 3 months
This study tests whether removing the ripcord from an implanted glaucoma drainage device changes eye pressure for adults with open-angle glaucoma.
-
Glaucoma and Brain Changes: How Brain Structure and Size See What Glaucoma Is Doing
This study tests whether glaucoma is linked to broader brain changes by comparing brain MRI and eye health over time in people with glaucoma and matched controls.
-
Long-Term Results After Ab-interno Trabeculotomy for Glaucoma
This study tests whether ab-interno trabeculotomy with the Trabectome can provide sustained intraocular pressure reduction in glaucoma patients who had the procedure between 2019 and 2021.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.